Board of Directors
Investors and Partners
Ceftibuten / VNRX-7145
News & Events
In the News
Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor
Discovery and preclinical profile of VNRX-9945, a potent, broadly active core protein inhibitor for the treatment of chronic hepatitis B virus (HBV) infection
Rescue of Ceftibuten Activity by the Oral Beta-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing Class A, C and/or D Beta-Lactamases.
Evaluation of the
activity of cefepime plus taniborbactam (formerly VNRX-5133) and comparative agents against carbapenem-resistant Enterobacteriaceae.
You are using a browser that is not supported. Please consider changing your browser